<DOC>
	<DOCNO>NCT02812654</DOCNO>
	<brief_summary>Prospective phase II study . Patients submit neoadjuvant chemotherapy ( cT ) hypo fractionate radiotherapy ( hRT ) follow surgery . The remain viable cell analyzed patient whithin less 30 % receive 3 cycle cT. All patient deep high grade soft tissue sarcoma extremity .</brief_summary>
	<brief_title>Ifosfamide , Doxorubicin Hypofractionated Radiotherapy Neoadjuvant Sarcoma Treatment</brief_title>
	<detailed_description>Prospective phase II non control study . Staging : All patient submit local Magnetic Resonance ( MR ) , Chest Tomography ( CT ) Positron emission tomography-computed tomography ( PET CT ) previous treatment . After first cT cycle new PET CT provide one end neoadjuvant treatment . Chemotherapy : cT neoadjuvant : Doxorubicin 75mg/m2 ( cycle 1,2 3 ) , ifosfamide 9 g/m2 ( cycle 1 3 ) . Radiotherapy : RT 25 Gy / 5 x 500 cGy/day , begin Cycle 2/Day1 . The surgery perform 4-6 week cycle 3 . The remain viable cell surgical specimen analyze whether percentage value less 30 % patient receive 3 cycle cT. A boost RT indicate margin consider R1 ( microscopic positive margin ) .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Patients 1875 year old , non metastatic deeply high grade soft tissue sarcoma extremity . KPS &gt; 70 % ( Karnofsky Performance Status Score ) Patients rhabdomyosarcoma , neuroendocrine tumor ( Pnet ) chondrosarcoma , receive radiotherapy ( RT ) chemotherapy ( cT ) previous , recurrent tumor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Sarcoma</keyword>
	<keyword>soft tissue sarcoma</keyword>
	<keyword>neoadjuvant chemotherapy</keyword>
	<keyword>neoadjuvant radiotherapy</keyword>
	<keyword>hypofractionated radiotherapy</keyword>
</DOC>